Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 3/20 | 0.57 |
| ▸ | DHODH | Q02127 | 3/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.36 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18280283 | 0.83 | TNF (0.63) | TNFPDE4BPDE4D | |
| SCHEMBL18280281 | 0.81 | TNF (0.68) | TNFDHODHKDRPDE4BPDE4D | |
| SCHEMBL18280291 | 0.81 | TNF (0.64) | TNFDHODHABCG2LMNAKDR | |
| SCHEMBL15055239 | 0.81 | TNF (0.60) | TNFDHODHPDE4BPDE4D | |
| SCHEMBL15055192 | 0.80 | TNF (0.62) | TNFLMNAKDRPDE4BPDE4D | |
| Bromide SCHEMBL15055004 | 0.79 | TNF (0.61) | TNFLMNAKDRPDE4BPDE4D | |
| SCHEMBL18280288 | 0.78 | TNF (0.57) | TNFKDR | |
| SCHEMBL17509926 | 0.78 | NPC1 (0.55) | TRPV1 | |
| SCHEMBL16182554 | 0.77 | TNF (0.37) | TNFDHODHTRPV1LMNATYR | |
| SCHEMBL18280285 | 0.76 | TNF (0.55) | TNFPDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9889139-B2 | Method of treating inflammatory bowel disease comprising administering a pharmaceutical composition comprising a 6-aminopyridin-3-ol compound or a pharmaceutically acceptable salt thereof as an active ingredient to a subject | RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY (KR) | 2018-02-13 | — | — | US | claimed |
| US-20160354352-A1 | METHOD OF TREATING INFLAMMATORY BOWEL DISEASE COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING A 6-AMINOPYRIDIN-3-OL COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS AN ACTIVE INGREDIENT TO A SUBJECT | RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY (KR) | 2016-12-08 | — | — | US | claimed |
| US-9889139-B2 | Method of treating inflammatory bowel disease comprising administering a pharmaceutical composition comprising a 6-aminopyridin-3-ol compound or a pharmaceutically acceptable salt thereof as an active ingredient to a subject | RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY (KR) | 2018-02-13 | — | — | US | disclosed |
| US-9889139-B2 | Method of treating inflammatory bowel disease comprising administering a pharmaceutical composition comprising a 6-aminopyridin-3-ol compound or a pharmaceutically acceptable salt thereof as an active ingredient to a subject | RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY (KR) | 2018-02-13 | — | — | US | disclosed |
| US-9889139-B2 | Method of treating inflammatory bowel disease comprising administering a pharmaceutical composition comprising a 6-aminopyridin-3-ol compound or a pharmaceutically acceptable salt thereof as an active ingredient to a subject | RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY (KR) | 2018-02-13 | — | — | US | disclosed |
| US-20160354352-A1 | METHOD OF TREATING INFLAMMATORY BOWEL DISEASE COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING A 6-AMINOPYRIDIN-3-OL COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS AN ACTIVE INGREDIENT TO A SUBJECT | RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY (KR) | 2016-12-08 | — | — | US | disclosed |
| US-20160354352-A1 | METHOD OF TREATING INFLAMMATORY BOWEL DISEASE COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING A 6-AMINOPYRIDIN-3-OL COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS AN ACTIVE INGREDIENT TO A SUBJECT | RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY (KR) | 2016-12-08 | — | — | US | disclosed |
| US-20160354352-A1 | METHOD OF TREATING INFLAMMATORY BOWEL DISEASE COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING A 6-AMINOPYRIDIN-3-OL COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS AN ACTIVE INGREDIENT TO A SUBJECT | RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY (KR) | 2016-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354352-A1 | METHOD OF TREATING INFLAMMATORY BOWEL DISEASE COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING A 6-AMINOPYRIDIN-3-OL COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS AN ACTIVE INGREDIENT TO A SUBJECT | SI, SLC10A2, ALPI | TNF 100/4885DHODH 952/4885ABCG2 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.